Ozempic vs Wegovy: What's the Difference?

*This article is for informational purposes only. It is not medical advice. Speak with a licensed healthcare provider before starting any new medication or treatment program.*

---

If you have been researching Ozempic vs Wegovy, you may have noticed something confusing: both medications contain the exact same active ingredient. They are both semaglutide, made by the same manufacturer, and they work through the same biological mechanism. So why are they treated as different drugs?

The answer comes down to FDA approval, dosing, and intended use. Understanding the distinction helps you have a more informed conversation with your provider about which path makes sense for your situation.

---

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist, a class of medications that mimics a naturally occurring hormone called glucagon-like peptide-1. GLP-1 is released from the gut after eating and plays several roles in metabolism: it stimulates insulin release in response to blood sugar, slows the rate at which the stomach empties, and signals the brain to reduce appetite.

As a synthetic GLP-1 analogue, semaglutide activates these same receptors. That is the molecular basis for both its blood sugar lowering effects and its weight loss effects. The molecule itself is identical in Ozempic and Wegovy. What differs is the approved indication and the maximum dose.

---

What Is Ozempic?

Ozempic is a brand-name semaglutide injection manufactured by Novo Nordisk and FDA-approved for improving blood sugar control in adults with type 2 diabetes. The FDA granted approval in December 2017.

Ozempic is available as a subcutaneous injection given once weekly. The dose starts at 0.5 mg weekly and can be titrated up to 1 mg or 2 mg depending on how well the medication is tolerated and how blood sugar responds.

Ozempic is not FDA-approved for weight loss. Novo Nordisk conducted separate clinical trials, obtained a separate FDA approval, and brought a separate product to market for that indication. That product is Wegovy.

---

What Is Wegovy?

Wegovy is also a brand-name semaglutide injection made by Novo Nordisk, approved by the FDA in June 2021 specifically for chronic weight management in adults with obesity (BMI 30 or greater) or adults with overweight (BMI 27 or greater) who also have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol.

The key difference from Ozempic is the maximum dose. Wegovy titrates up to 2.4 mg weekly, which is higher than Ozempic's ceiling of 2 mg. That higher dose ceiling is what the weight loss trials were built around.

A landmark clinical trial, the STEP 1 study published in the *New England Journal of Medicine*, found that adults with overweight or obesity who used semaglutide 2.4 mg weekly alongside lifestyle intervention lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group [1]. This evidence base is what the FDA reviewed when it approved Wegovy for weight management.

---

*Both Ozempic and Wegovy require a prescription from a licensed healthcare provider. Your eligibility depends on your specific medical history and health goals.*

---

The Key Differences: A Quick Comparison

Why People Use Ozempic Off-Label for Weight Loss

Because Ozempic and Wegovy contain the same molecule, semaglutide's weight loss properties are present regardless of which brand is prescribed. This has led to widespread off-label prescribing of Ozempic for weight management, particularly for patients whose insurance does not cover Wegovy or who have difficulty accessing it.

Off-label prescribing is legal in the United States. A licensed provider may prescribe an approved medication for a use other than its FDA-approved indication when they determine it is medically appropriate for a specific patient. However, the dose ceiling for off-label Ozempic use is 2 mg rather than 2.4 mg, and the prescribing data is built around a different maximum dose than the weight loss trials used.

The shortage implications have been significant. As demand for semaglutide grew after Wegovy's approval, supply constraints created ongoing access problems for both products. At various points between 2023 and 2025, patients with Ozempic prescriptions for diabetes management struggled to fill their medications as demand from off-label weight loss users increased. The FDA placed semaglutide on its drug shortage list during peak demand periods.

---

Cost Without Insurance

List prices for semaglutide are high regardless of which brand you are looking at.

Ozempic carries a monthly list price of approximately $900 or more without insurance. For patients with type 2 diabetes who have commercial insurance with a drug benefit, coverage is more common, but prior authorization requirements and co-pay tiers vary significantly.

Wegovy carries a monthly list price of approximately $1,350 without insurance. Insurance coverage for Wegovy has been less consistent than for Ozempic. Many commercial insurance plans and Medicare Part D plans do not include Wegovy on their formularies, or impose strict prior authorization criteria, because weight loss indications have historically received lower insurance priority than diabetes treatment.

Novo Nordisk has offered manufacturer savings programs for both products, but eligibility restrictions apply and these programs are typically unavailable to Medicare beneficiaries.

---

Compounded Semaglutide as an Affordable Alternative

For patients who are medically appropriate candidates for semaglutide-based treatment but face cost barriers, compounded semaglutide from a licensed 503A compounding pharmacy is one option that exists in the market.

Compounded semaglutide programs through licensed telehealth providers typically cost between $200 and $350 per month, a significant difference from the $900 to $1,350 monthly list prices of branded products.

There is an important distinction to understand clearly. Compounded semaglutide is not FDA-approved and is not the same as Ozempic or Wegovy. The FDA has not reviewed any compounded semaglutide formulation for safety, efficacy, or quality in the same way it reviewed branded products. Compounded semaglutide is a legally prepared medication made by a licensed compounding pharmacy using semaglutide as the active pharmaceutical ingredient. It is a different product operating in a different regulatory category.

The SELECT trial, published in the *New England Journal of Medicine* in 2023, found that semaglutide 2.4 mg weekly reduced the risk of major cardiovascular events by 20% in adults with established cardiovascular disease and overweight or obesity who did not have diabetes [2]. This research was conducted using the branded Wegovy formulation at its approved dose and cannot be used to draw conclusions about compounded formulations.

If you are considering compounded semaglutide, work with a provider who understands the current regulatory landscape and can verify that the pharmacy they use is operating under full compliance with state and federal compounding law.

---

How to Get a Prescription Online

Both Ozempic and Wegovy require a prescription from a licensed healthcare provider. Neither is available over the counter.

Online telehealth platforms allow you to complete an eligibility assessment, have a medical evaluation with a licensed provider, and, if appropriate, receive a prescription that is filled and shipped directly to you. The process typically takes a few days from evaluation to delivery.

For patients interested in exploring their options, including whether they qualify for semaglutide-based treatment, Prescriva connects you with independently licensed providers who evaluate your specific medical history and health goals.

[Check your eligibility with Prescriva](/quiz)

---

Frequently Asked Questions

Are Ozempic and Wegovy the same thing? They contain the same active ingredient (semaglutide) but they are different FDA-approved products with different indications, different maximum doses, and different pricing. Ozempic is approved for type 2 diabetes; Wegovy is approved for chronic weight management.

Can a doctor prescribe Ozempic for weight loss? Yes, off-label prescribing is legal. A provider can prescribe Ozempic for weight management if they determine it is medically appropriate. However, the maximum dose available in Ozempic (2 mg) is lower than the 2.4 mg dose studied in Wegovy's weight loss trials.

Which one is better for weight loss? Wegovy is specifically approved for weight management at the 2.4 mg dose that the STEP 1 trial studied. If weight loss is your primary goal, Wegovy is the on-label option. Whether you can access it depends on insurance coverage, availability, and cost considerations.

Is there a generic version of Ozempic or Wegovy? No. There is currently no FDA-approved generic semaglutide injection. Compounded semaglutide is sometimes described colloquially as a "generic," but this is inaccurate. Compounded semaglutide is not a generic drug. It is a compounded medication that is not FDA-approved and is not the same product as Ozempic or Wegovy.

Why does Wegovy cost more than Ozempic? Novo Nordisk prices them differently because they target different indications and patient populations. Insurance reimbursement dynamics, the higher dose (2.4 mg vs. 2 mg), and the separate development and approval pathway for Wegovy all contribute to the price difference.

---

See Also

• [Compounded Semaglutide vs. Ozempic: Are They the Same Thing?](/resources/compounded-semaglutide-vs-ozempic)
• [Compounded Semaglutide Cost in 2026: What to Expect](/resources/compounded-semaglutide-cost-2026)
• [Mounjaro vs. Ozempic vs. Wegovy: Which GLP-1 Is Right for You?](/resources/mounjaro-vs-ozempic-vs-wegovy-2026)

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." *New England Journal of Medicine*. 2021;384(11):989-1002. [PMID: 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/). DOI: 10.1056/NEJMoa2032183

1. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.; SELECT Trial Investigators. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." *New England Journal of Medicine*. 2023;389(24):2221-2232. [PMID: 37952131](https://pubmed.ncbi.nlm.nih.gov/37952131/). DOI: 10.1056/NEJMoa2307563

1. U.S. Food and Drug Administration. "[Ozempic (semaglutide) injection, for subcutaneous use — Prescribing Information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf)." FDA.gov. 2017.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.

Compounding Disclaimer: Compounded semaglutide is not an FDA-approved medication. Compounded drugs are not reviewed by the FDA for safety, efficacy, or quality. Compounded semaglutide is not the same as, equivalent to, or interchangeable with FDA-approved semaglutide products (Ozempic, Wegovy, or Rybelsus).

Results Disclaimer: Individual results vary. Weight management outcomes depend on adherence to your prescribed treatment plan, diet, exercise, starting weight, and other individual health factors. Results are not guaranteed.

Provider Disclaimer: All medical services, including prescribing, are provided by independently licensed healthcare providers. Blue Oak Services LLC dba Prescriva is a management services organization and does not practice medicine or make clinical decisions.

Brand Disclaimer: Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Prescriva is not affiliated with, endorsed by, or sponsored by Novo Nordisk A/S.